CD274 and non-small cell lung carcinoma: From an initial population of 26,361 curated patients available in the NSCLC database, 3886 patients met all criteria and were started on first-line therapy in the study period, and 2175 of these were treated with an anti–PD-1/PD-L1 agent in the first line during the specified period and were included in the study cohort (Fig. 2).